[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Haematology](https://durgical.com/en/haematology/) › [Lymphoma and plasma cells](https://durgical.com/en/haematology/areas/lymphoid/) › CLL: MBL, Rai and Binet stages, when to treat

# CLL: MBL, Rai and Binet stages, when to treat

- Treatment and support

Most people with early CLL live for years without treatment. Knowing when to treat, and when not to, is the core skill.

Updated Nov 15, 2026

## Key points

- MBL below 5 × 10⁹/L clonal B cells; CLL at or above, sustained.
- Rai: 0 blood, I nodes, II [spleen](https://durgical.com/en/anatomy/spleen/) or [liver](https://durgical.com/en/anatomy/liver/), III anaemia, IV platelets.
- Binet: A fewer than three areas, B three or more, C cytopenias.
- Treat active disease only; high count alone is not a reason.
- Test TP53 and IGHV before treatment; BTK or BCL2 inhibitors are the backbone.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- How it is done (and why)
- Common traps
- Elsewhere in DurgiPedia

- Safety Risks and precautions
- Monitoring and next step

- Study Test yourself

- Connections Connections

## What it is

[Chronic lymphocytic leukaemia](https://durgical.com/en/conditions/chronic-lymphocytic-leukaemia/) (CLL) is staged by where the disease is and whether it has pushed out normal blood cells. Monoclonal B-cell lymphocytosis (MBL) is a small clone of CLL-like cells below the CLL threshold, without nodes, organ enlargement or symptoms. The Rai and Binet systems sort CLL by nodes, spleen and liver and, most importantly, by anaemia and low platelets from marrow infiltration. Treatment starts only when the disease is active, guided by [genetic tests](https://durgical.com/en/biochemistry/topics/genetic-tests-what-each-one-finds/) (TP53 and IGHV status). Targeted drugs, Bruton [tyrosine](https://durgical.com/en/biochemistry/molecules/tyrosine/) kinase (BTK) inhibitors and the BCL2 inhibitor [venetoclax](https://durgical.com/en/pharmacology/venetoclax/), have largely replaced chemotherapy.

## How to think about it

Think of CLL as a slow tide of cells filling a harbour. First the water is only in the channel (lymphocytes in the blood), then it floods the docks (nodes, spleen, liver), and finally it swamps the boatyard where new boats are built (the marrow, causing anaemia and low platelets). Staging asks how far the tide has come; treatment waits until the water is actually damaging something.

## What to know

- MBL: clonal B cells below 5 × 10⁹/L, with no nodes, organ enlargement, cytopenias or symptoms; CLL: clonal B cells at or above 5 × 10⁹/L.
- Small lymphocytic lymphoma (SLL) is the same disease living mainly in nodes, with fewer cells in the blood.
- Rai stages: 0 lymphocytosis only; I nodes; II spleen or liver; III anaemia; IV low platelets (below 100 × 10⁹/L). Grouped as low (0), intermediate (I–II) and high (III–IV) risk.
- Binet stages count five areas (neck, armpit and groin nodes, spleen, liver): A fewer than three areas; B three or more; C anaemia or low platelets.
- Cytopenias from autoimmune destruction (AIHA, ITP) do not count for stage III, IV or C, which mean marrow failure.
- Early asymptomatic CLL is watched: treating early has not improved survival.
- TP53 deletion or mutation and unmutated IGHV predict a worse course and steer drug choice; TP53-abnormal disease does poorly with chemotherapy.

## How it is done (and why)

- Confirm the clone by blood flow cytometry; count clonal B cells to separate MBL from CLL.
- Stage by examination and count (Rai or Binet); imaging is not needed for early-stage staging.
- Is it active? Worsening marrow failure, bulky or painful nodes or spleen, a fast-rising count, B symptoms or steroid-resistant immune cytopenias.
- No active disease: watch and wait, with counts and examination every few months at first.
- Active disease: test TP53 ([FISH](https://durgical.com/en/histology/immunohistochemistry-and-in-situ-hybridization/) for 17p deletion and mutation) and IGHV status before choosing treatment.
- Choose: a continuous BTK inhibitor or fixed-duration venetoclax with an anti-CD20 antibody; chemoimmunotherapy only for selected fit patients.
- Repeat TP53 testing before each new line, because the clone can evolve.

## Risks and precautions

- Infections are the main cause of death: low antibody levels, poor vaccine responses and treatment effects all add up; vaccinate against [pneumococcus](https://durgical.com/en/microbiology/streptococcus-pneumoniae/), [influenza](https://durgical.com/en/conditions/influenza/) and others, and avoid live vaccines.
- Immunoglobulin replacement is considered for recurrent serious bacterial infections with low IgG.
- Venetoclax kills CLL cells fast, so [tumour lysis syndrome](https://durgical.com/en/conditions/tumour-lysis-syndrome/) is prevented with a gradual start, hydration and monitoring.
- [BTK inhibitors](https://durgical.com/en/pharmacology/classes/btk-inhibitors/) can cause [atrial fibrillation](https://durgical.com/en/conditions/atrial-fibrillation/), high [blood pressure](https://durgical.com/en/physiology/systolic-diastolic-mean-and-pulse-pressure/) and bleeding; they need a plan around surgery and caution with anticoagulants.
- Rapidly enlarging nodes, fever, weight loss or a high LDH suggest Richter transformation to an aggressive lymphoma and need a biopsy, ideally guided by PET-CT.
- Skin cancers and other second cancers are more common, so skin checks are part of follow-up.

## Monitoring and next step

- Watch-and-wait visits: blood count, examination of nodes, spleen and liver, and symptoms.
- Before treatment: FISH for 17p deletion, TP53 mutation, IGHV mutation status, kidney and liver tests, hepatitis B serology (reactivation risk with anti-CD20 [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/)).
- New anaemia: reticulocytes and direct antiglobulin test to tell autoimmune haemolysis from marrow failure.
- IgG level when infections recur.
- After fixed-duration treatment, measurable residual disease by flow cytometry shows the depth of response.

## Common traps

- **Starting treatment because the lymphocyte count is very high**: a high count alone is not an indication; symptoms, marrow failure or bulky disease are
- **Staging a patient as Rai III because of anaemia from autoimmune haemolysis**: immune cytopenias are treated separately and do not define stage
- **Calling every small B-cell clone in an older adult leukaemia**: below the CLL threshold and without disease features it is MBL, which needs only follow-up
- **Choosing chemoimmunotherapy without testing TP53**: TP53-abnormal CLL responds poorly to chemotherapy and needs targeted drugs
- **Forgetting hepatitis B before anti-CD20 antibodies**: reactivation can cause fatal hepatitis

## Test yourself

Think of the answer, then tap the question to see it.

## A 68-year-old has a lymphocyte count of 30 × 10⁹/L, no symptoms, small neck nodes and a normal haemoglobin and platelet count. Should treatment start?

No: this is early CLL (Rai I, Binet A) without active disease. A high count alone is not an indication; watch and wait with regular counts and examination.

## A man with CLL becomes anaemic; reticulocytes are high and the direct antiglobulin test is positive. Does this make him Rai stage III?

No: the anaemia is autoimmune haemolysis, not marrow failure. It is treated on its own terms and does not define the stage.

## Why is TP53 tested before every new line of CLL treatment?

TP53 loss predicts a poor response to chemotherapy and can be acquired as the clone evolves, so a result from diagnosis may no longer be true.

## A woman with known CLL develops fever, weight loss and one rapidly growing node with a high LDH. What should be done next?

Biopsy the node, ideally the most PET-avid one, to look for Richter transformation into an aggressive lymphoma, which is treated differently.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/haematology/cll-mbl-rai-and-binet-stages-when-to-treat/)

## Elsewhere in DurgiPedia

- [Chronic lymphocytic leukaemia (CLL/SLL)](https://durgical.com/en/general-pathology/chronic-lymphocytic-leukaemia/)
- [Clonality testing: telling lymphoma from a reactive response](https://durgical.com/en/immunology/clonality-testing-telling-lymphoma-from-a-reactive-response/)
- [Secondary immunodeficiency: HIV, malnutrition, drugs, asplenia](https://durgical.com/en/immunology/secondary-immunodeficiency-hiv-malnutrition-drugs-asplenia/)
- [Leukaemia, lymphoma and stem-cell transplant: nursing care and graft-versus-host warning signs](https://durgical.com/en/nursing/leukaemia-lymphoma-and-stem-cell-transplant-nursing-care-and-graft-versus-host-w/)

## Connections

## Related 6

- [Chronic leukaemias: CML versus CLL (and hairy cell leukaemia)](https://durgical.com/en/haematology/chronic-leukaemias-cml-versus-cll/)
- [A high or low white count: which cell, and is it mature?](https://durgical.com/en/haematology/a-high-or-low-white-count-which-cell-and-is-it-mature/)
- [High lymphocytes or monocytes: reactive, MBL/CLL or CMML?](https://durgical.com/en/haematology/high-lymphocytes-or-monocytes-reactive-mbl-cll-or-cmml/)
- [Autoimmune haemolysis: warm, cold and drug-induced](https://durgical.com/en/haematology/autoimmune-haemolysis-warm-cold-and-drug-induced/)
- [Tumour lysis syndrome: prevent, recognise, treat](https://durgical.com/en/haematology/tumour-lysis-syndrome-prevent-recognise-treat/)
- [Supportive care in blood cancers](https://durgical.com/en/haematology/supportive-care-in-blood-cancers/)

## Related conditions 4

- [Chronic lymphocytic leukaemia](https://durgical.com/en/conditions/chronic-lymphocytic-leukaemia/)
- [Autoimmune haemolytic anaemia](https://durgical.com/en/conditions/autoimmune-haemolytic-anaemia/)
- [Immune thrombocytopenia (ITP)](https://durgical.com/en/conditions/immune-thrombocytopenia/)
- [Non-Hodgkin lymphoma](https://durgical.com/en/conditions/non-hodgkin-lymphoma/)

[← All of haematology](https://durgical.com/en/haematology/)

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: [Chronic Lymphocytic Leukemia](https://www.ncbi.nlm.nih.gov/books/NBK470433/) (StatPearls (NCBI Bookshelf), 2023); [Chronic Lymphocytic Leukemia Treatment (PDQ®)–Patient Version](https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq) (National Cancer Institute (NCI), 2026); [Monoclonal B-Cell Lymphocytosis: The Silent Clone the Haematologists Should Not Neglect](https://pmc.ncbi.nlm.nih.gov/articles/PMC12167647/) (Hematological Oncology (PMC open access), 2025).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/haematology/cll-mbl-rai-and-binet-stages-when-to-treat/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/haematology/cll-mbl-rai-and-binet-stages-when-to-treat/
